Volatomics in inflammatory bowel disease and irritable bowel syndrome

Kathleen Van Malderen, Benedicte Y De Winter, Joris G De Man, Heiko U De Schepper, Kevin Lamote, Kathleen Van Malderen, Benedicte Y De Winter, Joris G De Man, Heiko U De Schepper, Kevin Lamote

Abstract

Volatile organic compounds (VOCs) are produced by the human metabolism, inflammation and gut microbiota and form the basis of innovative volatomics research. VOCs detected through breath and faecal analysis hence serve as attractive, non-invasive biomarkers for diagnosing and monitoring irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). This review describes the clinical applicability of volatomics in discriminating between IBS, IBD and healthy volunteers with acceptable accuracy in breath (70%-100%) and faecal (58%-85%) samples. Promising compounds are propan-1-ol for diagnosing and monitoring of IBD patients, and 1-methyl-4-propan-2-ylcyclohexa-1,4-diene as biomarker for IBS diagnosis. However, these VOCs often seem to be related to inflammation and probably will need to be used in conjunction with other clinical evidence. Furthermore, three interventional studies underlined the potential of VOCs in predicting treatment outcome and patient follow-up. This shows great promise for future use of VOCs as non-invasive breath and faecal biomarkers in personalised medicine. However, properly designed studies that correlate VOCs to IBD/IBS pathogenesis, while taking microbial influences into account, are still key before clinical implementation can be expected.

Keywords: IBD; IBS; Irritable bowel syndrome; VOC; Volatile organic compounds; inflammatory bowel disease.

Conflict of interest statement

Declaration of Competing Interest The authors declare no personal conflict of interests.

Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.

Figures

Fig. 1
Fig. 1
Individual VOCs in IBD and IBS. Compounds described in more than one study are in bold. ↑: upregulated. ↓: downregulated.
Fig. 2
Fig. 2
The potential of VOC analysis in the management of IBS and IBD. VOCs can originate from metabolic processes, both physiologic and pathophysiologic (inflammation or oxidative stress), and by the microbiota. Hence, a flare up or change in micobial composition can be reflected in VOC changes. However, this also stresses the potential of confounding external factors like drugs and diet that need to be accounted for. VOCs are liberated by the gastrointestinal cells and can be excreted in faeces, but are also transported through the bloodstream and can hence be detected in breath and urine, offering non-invasive alternatives for future disease management.

References

    1. Canavan C., West J., Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014;6:71–80.
    1. Marley A.R., Nan H. Epidemiology of colorectal cancer. Int J Mol Epidemiol Genet. 2016;7(3):105–114.
    1. Gujral N., Freeman H.J., Thomson A.B. Celiac disease: prevalence, diagnosis, pathogenesis and treatment. World J Gastroenterol. 2012;18(42):6036–6059.
    1. Ng S.C., Shi H.Y., Hamidi N. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390(10114):2769–2778.
    1. Schoepfer A.M., Trummler M., Seeholzer P., Seibold-Schmid B., Seibold F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis. 2008;14(1):32–39.
    1. De Schepper H.U., De Man J.G., Moreels T.G., Pelckmans P.A., De Winter B.Y. Review article: gastrointestinal sensory and motor disturbances in inflammatory bowel disease - clinical relevance and pathophysiological mechanisms. Aliment Pharmacol Ther. 2008;27(8):621–637.
    1. Zhang L., Song J., Hou X. Mast cells and irritable bowel syndrome: from the bench to the bedside. J Neurogastroenterol Motil. 2016;22(2):181–192.
    1. Defrees D.N., Bailey J. Irritable bowel syndrome: epidemiology, pathophysiology, diagnosis, and treatment. Prim Care. 2017;44(4):655–671.
    1. Hungin A.P., Whorwell P.J., Tack J., Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther. 2003;17(5):643–650.
    1. Lacy B.E., Patel N.K. Rome criteria and a diagnostic approach to irritable bowel syndrome. J Clin Med. 2017;6(11):99.
    1. Burisch J., Jess T., Martinato M., Lakatos P.L., EpiCom E. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7(4):322–337.
    1. Wang Z.H., Fang J.Y. Colorectal cancer in inflammatory bowel disease: epidemiology, pathogenesis and surveillance. Gastrointest Tumors. 2014;1(3):146–154.
    1. Kim D.H., Cheon J.H. Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies. Immune Netw. 2017;17(1):25–40.
    1. Yanai H., Hanauer S.B. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106(4):685–698.
    1. Waugh N., Cummins E., Royle P. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess. 2013;17(55):xv–xix. 1-211.
    1. Wang L., Mannalithara A., Singh G., Ladabaum U. Low rates of gastrointestinal and non-gastrointestinal complications for screening or surveillance colonoscopies in a population-based study. Gastroenterology. 2018;154(3) 540-555.
    1. Rajilic-Stojanovic M., Jonkers D.M., Salonen A. Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena. Am J Gastroenterol. 2015;110(2):278–287.
    1. Sundin J., Ohman L., Simren M. Understanding the gut microbiota in inflammatory and functional gastrointestinal diseases. Psychosom Med. 2017;79(8):857–867.
    1. Falony G., Joossens M., Vieira-Silva S. Population-level analysis of gut microbiome variation. Science. 2016;352(6285):560–564.
    1. Romano A., Capozzi V., Spano G., Biasioli F. Proton transfer reaction-mass spectrometry: online and rapid determination of volatile organic compounds of microbial origin. Appl Microbiol Biotechnol. 2015;99(9):3787–3795.
    1. Rondanelli M., Perdoni F., Infantino V. Volatile organic compounds as biomarkers of gastrointestinal diseases and nutritional status. J Anal Methods Chem. 2019;2019
    1. Brusselmans L., Arnouts L., Millevert C., Vandersnickt J., van Meerbeeck J.P., Lamote K. Breath analysis as a diagnostic and screening tool for malignant pleural mesothelioma: a systematic review. Transl Lung Cancer Res. 2018;7(5):520–536.
    1. Lamote K., Nackaerts K., van Meerbeeck J.P. Strengths, weaknesses, and opportunities of diagnostic breathomics in pleural mesothelioma-a hypothesis. Cancer Epidemiol Biomarkers Prev. 2014;23(6):898–908.
    1. Baranska A., Mujagic Z., Smolinska A. Volatile organic compounds in breath as markers for irritable bowel syndrome: a metabolomic approach. Aliment Pharmacol Ther. 2016;44(1):45–56.
    1. Amann A., Costello Bde L., Miekisch W. The human volatilome: volatile organic compounds (VOCs) in exhaled breath, skin emanations, urine, feces and saliva. J Breath Res. 2014;8(3)
    1. Haick H., Broza Y.Y., Mochalski P., Ruzsanyi V., Amann A. Assessment, origin, and implementation of breath volatile cancer markers. Chem Soc Rev. 2014;43(5):1423–1449.
    1. Rezaie A., Buresi M., Lembo A. Hydrogen and methane-based breath testing in gastrointestinal disorders: the north american consensus. Am J Gastroenterol. 2017;112(5):775–784.
    1. Siddiqui I., Ahmed S., Abid S. Update on diagnostic value of breath test in gastrointestinal and liver diseases. World J Gastrointest Pathophysiol. 2016;7(3):256–265.
    1. de Lacy Costello B.P., Ledochowski M., Ratcliffe N.M. The importance of methane breath testing: a review. J Breath Res. 2013;7(2)
    1. Downes M.J., Brennan M.L., Williams H.C., Dean R.S. Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS) BMJ Open. 2016;6(12)
    1. Allen M.S., Walter E.E., Swann C. Sedentary behaviour and risk of anxiety: a systematic review and meta-analysis. J Affect Disord. 2019;242:5–13.
    1. Ahmed I., Greenwood R., Costello Bde L., Ratcliffe N.M., Probert C.S. An investigation of fecal volatile organic metabolites in irritable bowel syndrome. PLoS ONE. 2013;8(3):e58204.
    1. Arasaradnam R.P., Westenbrink E., McFarlane M.J. Differentiating coeliac disease from irritable bowel syndrome by urinary volatile organic compound analysis–a pilot study. PLoS ONE. 2014;9(10)
    1. Shepherd S.F., McGuire N.D., de Lacy Costello B.P. The use of a gas chromatograph coupled to a metal oxide sensor for rapid assessment of stool samples from irritable bowel syndrome and inflammatory bowel disease patients. J Breath Res. 2014;8(2)
    1. Rossi M., Aggio R., Staudacher H.M. Volatile organic compounds in feces associate with response to dietary intervention in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2018;16(3) 385-91 e1.
    1. Aggio R.B., White P., Jayasena H., de Lacy Costello B., Ratcliffe N.M., Probert C.S. Irritable bowel syndrome and active inflammatory bowel disease diagnosed by faecal gas analysis. Aliment Pharmacol Ther. 2017;45(1):82–90.
    1. Walton C., Fowler D.P., Turner C. Analysis of volatile organic compounds of bacterial origin in chronic gastrointestinal diseases. Inflamm Bowel Dis. 2013;19(10):2069–2078.
    1. Cauchi M., Fowler D.P., Walton C. Application of gas chromatography mass spectrometry (GC–MS) in conjunction with multivariate classification for the diagnosis of gastrointestinal diseases. Metabolomics. 2014;10(6):1113–1120.
    1. Kokoszka J., Nelson R.L., Swedler W.I., Skosey J., Abcarian H. Determination of inflammatory bowel disease activity by breath pentane analysis. Dis Colon Rectum. 1993;36(6):597–601.
    1. Rieder F., Kurada S., Grove D. A distinct colon-derived breath metabolome is associated with inflammatory bowel disease, but not its complications. Clin Transl Gastroenterol. 2016;7(11):e201.
    1. Arasaradnam R.P., McFarlane M., Daulton E. Non-invasive exhaled volatile organic biomarker analysis to detect inflammatory bowel disease (IBD) Dig Liver Dis. 2016;48(2):148–153.
    1. Garner C.E., Smith S., de Lacy Costello B. Volatile organic compounds from feces and their potential for diagnosis of gastrointestinal disease. FASEB J. 2007;21(8):1675–1688.
    1. Kumari R., Ahuja V., Paul J. Fluctuations in butyrate-producing bacteria in ulcerative colitis patients of North India. World J Gastroenterol. 2013;19(22):3404–3414.
    1. Hicks L.C., Huang J., Kumar S. Analysis of exhaled breath volatile organic compounds in inflammatory bowel disease: a pilot study. J Crohns Colitis. 2015;9(9):731–737.
    1. Ahmed I., Greenwood R., Costello B., Ratcliffe N., Probert C.S. Investigation of faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease. Aliment Pharmacol Ther. 2016;43(5):596–611.
    1. Walton C., Montoya M.P., Fowler D.P. Enteral feeding reduces metabolic activity of the intestinal microbiome in Crohn's disease: an observational study. Eur J Clin Nutr. 2016;70(9):1052–1056.
    1. Dryahina K., Smith D., Bortlik M., Machkova N., Lukas M., Spanel P. Pentane and other volatile organic compounds, including carboxylic acids, in the exhaled breath of patients with Crohn's disease and ulcerative colitis. J Breath Res. 2017;12(1)
    1. Dryahina K., Spanel P., Pospisilova V. Quantification of pentane in exhaled breath, a potential biomarker of bowel disease, using selected ion flow tube mass spectrometry. Rapid Commun Mass Spectrom. 2013;27(17):1983–1992.
    1. Pelli M.A., Trovarelli G., Capodicasa E., De Medio G.E., Bassotti G. Breath alkanes determination in ulcerative colitis and Crohn's disease. Dis Colon Rectum. 1999;42(1):71–76.
    1. Hovde O., Moum B.A. Epidemiology and clinical course of Crohn's disease: results from observational studies. World J Gastroenterol. 2012;18(15):1723–1731.
    1. Bolge S.C., Waters H., Piech C.T. Self-reported frequency and severity of disease flares, disease perception, and flare treatments in patients with ulcerative colitis: results of a national internet-based survey. Clin Ther. 2010;32(2):238–245.
    1. Nycyk J.A., Drury J.A., Cooke R.W. Breath pentane as a marker for lipid peroxidation and adverse outcome in preterm infants. Arch Dis Child Fetal Neonatal Ed. 1998;79(1):F67–F69.
    1. Bodelier A.G., Smolinska A., Baranska A. Volatile organic compounds in exhaled air as novel marker for disease activity in Crohn's disease: a metabolomic approach. Inflamm Bowel Dis. 2015;21(8):1776–1785.
    1. Smolinska A., Tedjo D.I., Blanchet L. Volatile metabolites in breath strongly correlate with gut microbiome in CD patients. Anal Chim Acta. 2018;1025:1–11.
    1. Tedelind S., Westberg F., Kjerrulf M., Vidal A. Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J Gastroenterol. 2007;13(20):2826–2832.
    1. Vinolo M.A., Rodrigues H.G., Nachbar R.T., Curi R. Regulation of inflammation by short chain fatty acids. Nutrients. 2011;3(10):858–876.
    1. Whitfield-Cargile C.M., Cohen N.D., Chapkin R.S. The microbiota-derived metabolite indole decreases mucosal inflammation and injury in a murine model of NSAID enteropathy. Gut Microbes. 2016;7(3):246–261.
    1. Di Cagno R., De Angelis M., De Pasquale I. Duodenal and faecal microbiota of celiac children: molecular, phenotype and metabolome characterization. BMC Microbiol. 2011;11:219.
    1. Francavilla R., Ercolini D., Piccolo M. Salivary microbiota and metabolome associated with celiac disease. Appl Environ Microbiol. 2014;80(11):3416–3425.
    1. Silva C.L., Passos M., Camara J.S. Investigation of urinary volatile organic metabolites as potential cancer biomarkers by solid-phase microextraction in combination with gas chromatography-mass spectrometry. Br J Cancer. 2011;105(12):1894–1904.
    1. Horvath I., Barnes P.J., Loukides S. A European Respiratory Society technical standard: exhaled biomarkers in lung disease. Eur Respir J. 2017;49(4)
    1. Couch R.D., Navarro K., Sikaroodi M. The approach to sample acquisition and its impact on the derived human fecal microbiome and voc metabolome. PLoS ONE. 2013;8(11):e81163.
    1. Bosch S., El Manouni El Hassani S., Covington J.A. Optimized sampling conditions for fecal volatile organic compound analysis by means of field asymmetric ion mobility spectrometry. Anal Chem. 2018;90(13):7972–7981.
    1. Gaulke C.A., Sharpton T.J. The influence of ethnicity and geography on human gut microbiome composition. Nat Med. 2018;24(10):1495–1496.
    1. Arasaradnam R.P., Quraishi N., Kyrou I. Insights into 'fermentonomics': evaluation of volatile organic compounds (VOCs) in human disease using an electronic 'e-nose'. J Med Eng Technol. 2011;35(2):87–91.
    1. Arasaradnam R.P., Ouaret N., Thomas M.G. A novel tool for noninvasive diagnosis and tracking of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(5):999–1003.
    1. Smolinska A., Bodelier A.G., Dallinga J.W. The potential of volatile organic compounds for the detection of active disease in patients with ulcerative colitis. Aliment Pharmacol Ther. 2017;45(9):1244–1254.
    1. Harris L.A., Baffy N. Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome. Postgrad Med. 2017;129(8):872–888.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa